The group, originating from the veterinary division of Zeltia, will produce vaccines for Europe in the event of a new health emergency. Your tuberculosis vaccine has arrived at a UN meeting.
Zendal has become a biopharmaceutical group in just a decade. It brings together eight companies that range from the development and manufacturing of veterinary vaccines (CZ Vaccines) and human (Biofabri), to the production of probiotics (Zinereo Pharma), distribution and laboratory activity (Vetia, Shepherd and Maymo) and services for veterinary professionals (Petia). In recent years there has been a strong growth, with purchases of companies
Zendal has become a biopharmaceutical group in just a decade. It brings together eight companies that range from the development and manufacturing of veterinary vaccines (CZ Vaccines) and human (Biofabri), to the production of probiotics (Zinereo Pharma), distribution and laboratory activity (Vetia, Shepherd and Maymo) and services for veterinary professionals (Petia). In recent years it has made a strong growth, with purchases of very specialized companies and also expanding its product offering.
Its starting point is in Zeltia Cooper (origin of the current PharmaMar), one of the four divisions of the company founded by the brothers José and Antonio Fernández López (the former also founder of Pescanova) during the post-war period to take advantage of slaughterhouse by-products in the production of pharmaceutical specialties. Its birth dates back to 1993, with the name CZ Veterinary and became the only Spanish company dedicated exclusively to the manufacture of veterinary products. Millions of doses of the Bluevac BTV8 vaccine came out of its laboratories to combat the bluetongue pandemic in Europe.
In 2018, with the promotion of the founder’s grandson, Andrés Fernández Álvarez-Santullanoto CEO, the company changes its skin again and is renamed Zendal in honor of the first nurse who participated in the international health expedition that set sail from the port of A Coruña in 1803. The management team – which they continue to lead in the presidency Pedro Fernández Puentes, from the second generation – conceived the transformation of the old CZ Veterinaria into a large biotechnology group. The Covid pandemic has given a boost to the conceived plan, although it had previously been reinforced with the acquisition of the former AstraZeneca plant in O Porriño, a town in Pontevedra where it has its main production center.
Zendal, through Biofabri – its human health subsidiary – has the single-dose vaccine against tuberculosis, MTBVAC, in phase 3 of a clinical trial.
This year, together with Reig Jofre, Zendal has been designated by the EU as vaccine manufacturer for future health emergencies. The company has completed its new plant of vaccines in Paredes de Coura (Portugal) which guarantees large-scale production. “The 2022 financial year constituted a transition space after which we concluded a period of consolidation, with new projects -both in animal and human health-, and new business areas that we hope will further strengthen our business group,” said the CEO. before the board.
Maintaining the commitment to research and innovation of its origins, Biofabri, the human vaccines division, has a project of great impact and very advanced: the single-dose tuberculosis vaccine, MTBVAC, which is in phase 3 of clinical trial. His name came up at the high-level meeting that the UN held this week on tuberculosis.
In the veterinary division, the company has developed Neolishwhich is the first vaccine with DNA technology in the world authorized by the European Medicines Agency (EMA) in animal mammals.
In addition, the group has become a leading player in biotechnological innovation: it has promoted the Galician investment fund Bio & Tech Smart Capital; It participates directly in disruptive start-ups and has launched the international Zendal Open Innovation awards, which constitutes a declaration of intent to anticipate what is going to happen in the long term.
Andrés Fernández Álvarez-Santullano has been the group’s CEO since 2018.
2023-09-21 22:43:11
#Zendal #Zeltias #brother #big #leap #Europe
